There’s a particular kind of Wall Street moment that tends to confuse retail investors when a company reports solid earnings, raises nothing alarming, and the stock falls anyway. Northrop Grumman (NOC) just had one of those.

The 32-year-old defense and aerospace giant reported first-quarter 2026 results that, by most measures, were fine. A modest earnings beat, reaffirmed full-year guidance, strong bookings, and a $96 billion backlog. Then the stock sold off. Not because the business was broken, but because of a number buried in the capital expenditure outlook that caught most investors off guard.

The culprit is the B-21 stealth bomber program, which is expanding, accelerating, and becoming more expensive in the near term.

“Northrop Grumman delivered strong first quarter results, with continued robust bookings, mid-single-digit organic sales growth, and solid operating performance,” said Northrop Grumman Chair and CEO Kathy Warden. “With our diverse portfolio, robust manufacturing capacity, and proven performance, we’re delivering differentiating technology at speed and scale.”

Morgan Stanley’s take on Northrup’s earnings report is more nuanced. The bank trimmed its price target to $745 from $765. A technical adjustment, not a loss of faith, given that it also told investors the selloff is a buying opportunity hiding in plain sight.

NOC’s B-21 expansion spooked investors, but MS disagrees

The number that moved Northrup’s stock price wasn’t on the income statement. It was in the capital expenditure guidance.

Northrop Grumman and the U.S. Air Force have jointly agreed to increase the B-21 Raider’s annual production rate by approximately 25%, according to the MS note. That decision is a vote of confidence in the platform, but it comes with a price tag. 

The production rate increase will require approximately $2.5 billion in multi-year investment, according to Morgan Stanley’s note, with the spending expected to manifest most meaningfully between 2027 and 2029.

Related: Morgan Stanley adjusts RTX price target after earnings

To accommodate that buildout, Northrop raised its 2026 capital expenditure estimate by approximately $200 million to roughly $1.85 billion. That’s a 12.4% increase from prior guidance, according to Morgan Stanley’s updated model. Full-year free cash flow guidance of $3.1 to $3.5 billion was held unchanged, as seen from the company’s earnings release, which the bank flags as notable given the incremental capex burden.

Morgan Stanley’s model now reflects the following updated estimates flowing through the B-21 investment cycle, according to the firm’s note:

  • 2026 adjusted EPS unchanged at $27.90; free cash flow lowered approximately 5% to roughly $3.28 billion after the capex raise
  • 2027 free cash flow estimated at approximately $3.4 billion
  • 2028 free cash flow estimated at approximately $3.64 billion
  • 2029 free cash flow estimated at approximately $4.16 billion

The trajectory matters. Near-term free cash flow takes a hit. Medium-term free cash flow recovers and grows. Morgan Stanley’s argument is that investors are pricing in the pain without pricing in the payoff.

NOC’s Q126 results show business doing well beneath the B-21 noise

Before the capital expenditure conversation dominated the post-earnings narrative, Northrop put up a solid quarter by any conventional measure. According to the company’s April earnings release, Q126 results were solid.

NOC’s first-quarter 2026 results included:

  • Sales of $9.9 billion, up 4% year over year; organic sales growth of 5%
  • Operating income of $989 million at a 10.0% margin rate
  • Diluted EPS of $6.14
  • Net awards of $9.8 billion and total backlog of $96 billion
  • Full-year 2026 guidance reaffirmed for sales of approximately $43.5 to $44 billion, EPS of $27.40 to $27.90, and free cash flow of $3.1 to $3.5 billion

The EPS beat against consensus was modest at approximately 1%, per Morgan Stanley’s note, aided in part by below-the-line items. Management held the full-year earnings outlook steady rather than lifting it. 

That combination, in a market already nervous about defense sector visibility, gave investors permission to sell first and ask questions later. Morgan Stanley’s view is that the questions, when asked, will eventually lead to a bullish answer.

The U.S. Navy is expected to award the F/A-XX fighter contract in August. Northrop and Boeing are competing, following the elimination of Lockheed Martin in March 2025.

Morgan Stanley also sees NOC’s portfolio uniquely positioned

Cheng Xin/Getty Images Morgan Stanley’s price target cut to $745 from $765 reflects valuation mechanics rather than a loss of faith. The bank uses a 31x multiple on 2027 estimated free cash flow per share of $24.05, a 25% premium it sees as justified by Northrop’s portfolio strength.

That strength is concentrated. About 35% of revenue ties to key programs. The missiles and missile defense (25%) and the B-21 (10%), both offering decades of production and sustainment revenue.

Related: Morgan Stanley has a message for ServiceNow investors

Northrop also controls two legs of the nuclear triad. The B-21 and Sentinel ICBM, with exposure to the third. These franchise programs provide long-term visibility and earnings stability.

According to The War Zone, a near-term catalyst could come in August, when the U.S. Navy is expected to award the F/A-XX fighter contract. Northrop and Boeing are competing, and a win would add another major next-generation platform not yet priced into estimates.

NOC selloff also reveals how defense investors are thinking in 2026

The market’s reaction to Northrop’s earnings reflects a broader tension running through defense sector investing right now. The gap between long-cycle program value and short-cycle free cash flow visibility.

With high interest rates and macro uncertainty, investors are hesitant to price in returns expected in 2028–2029, while cash flow is pressured today.

  • JPMorgan resets S&P 500 price target for the rest of 2026
  • Vanguard challenges the S&P 500 as a one-stop strategy
  • Goldman Sachs resets Broadcom stock forecast

More Wall Street Ultimately, Morgan Stanley argues this misses Northrop’s positioning. Global defense spending is rising, especially in missiles and missile defense, where the company is a leader. The B-21 production ramp was a joint decision with the U.S. Air Force, signaling strong demand and execution confidence.

Morgan Stanley is applying a 31 times free cash flow multiple, a 25% premium to the market, to a company it views as structurally advantaged in the programs that matter most to U.S. national security spending over the next decade. At $745, the bank sees that premium as not just justified but underpriced relative to the opportunity ahead.

Related: UBS adjusts price target on Alphabet stock